Compare Incyte Corporation (INCY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United Airlines Holdings Inc — how do they compare? Incyte Corporation trades at $117.62 (market cap $23.11B), while United Airlines Holdings Inc trades at $117.47 (market cap $38.15B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.
| INCY | UAL | |
|---|---|---|
Market Cap | $23.11B | $38.15B |
Sector | Health | Industrials |
52-Week High | $118.52 | $136.11 |
52-Week Low | $67.38 | $84.57 |
Enterprise Value | $19.13B | $55.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
United Airlines (UAL) trades at $116.77, up 1.18% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 10.81 and consistent earnings beats, including Q2 2026 EPS of $1.99 versus $1.88 expected. Revenue growth is robust, rising to $59.07B in 2025, though fuel costs pose headwinds. Analyst consensus is strongly bullish with a $163.75 price target and no sell ratings among 47 analysts.
Outlook remains positive due to resilient travel demand and premium revenue growth, but investors face risks from volatile fuel prices and operational disruptions. The stock offers value with low valuation multiples and upward earnings revisions, yet macroeconomic sensitivity requires caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
